Non-canonical variants and rearrangements in hairy cell leukemia.

Oncol Res

Cancer Molecular Diagnostics, St. James's Hospital, Dublin, D08 W9RT, Ireland.

Published: September 2024

AI Article Synopsis

  • * Most HCL patients have the V600E mutation, making it a key target for treating those who don't respond to standard therapies, but some may have different mutations.
  • * Diagnosing HCL patients without the V600E mutation requires careful evaluation for other genetic changes, which could reveal new insights into the disease and improve targeted treatment options.

Article Abstract

Hairy cell leukemia (HCL) is an uncommon mature B-cell malignancy characterized by a typical morphology, immunophenotype, and clinical profile. The vast majority of HCL patients harbor the canonical V600E mutation which has become a rationalized target of the subsequently deregulated RAS-RAF-MEK-MAPK signaling pathway in HCL patients who have relapsed or who are refractory to front-line therapy. However, several HCL patients with a classical phenotype display non-canonical mutations or rearrangements. These include sequence variants within alternative exons and an oncogenic fusion with the gene. Care must be taken in the molecular diagnostic work-up of patients with typical HCL but without the V600E to include investigation of these uncommon mechanisms. Identification, functional characterization, and reporting of further such patients is likely to provide insights into the pathogenesis of HCL and enable rational selection of targeted inhibitors in such patients if required.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11361905PMC
http://dx.doi.org/10.32604/or.2024.051218DOI Listing

Publication Analysis

Top Keywords

hcl patients
12
hairy cell
8
cell leukemia
8
hcl
6
patients
6
non-canonical variants
4
variants rearrangements
4
rearrangements hairy
4
leukemia hairy
4
leukemia hcl
4

Similar Publications

Approach to the Patient using Diabetes Technology in Pregnancy.

J Clin Endocrinol Metab

January 2025

Section of Maternal Fetal Medicine, Obstetrics and Gynecology, University of Chicago.

Diabetes in pregnancy increases risk for complications for the pregnant patient and neonate. Tight glycemic control to maintain glucose levels as close to non-diabetic ranges as possible can lower risk for these complications. Achieving strict glycemic targets can be challenging and technologies including continuous glucose monitors (CGM) and hybrid closed loop (HCL) insulin pumps have the potential to improve diabetes control and pregnancy outcomes.

View Article and Find Full Text PDF

Purpose: In patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), brentuximab vedotin (BV) as monotherapy or combined with either lenalidomide (Len) or rituximab (R) has demonstrated efficacy with acceptable safety. We evaluated the efficacy and safety of BV + Len + R versus placebo + Len + R in patients with R/R DLBCL.

Methods: ECHELON-3 is a randomized, double-blind, placebo-controlled, multicenter, phase 3 trial comparing BV + Len + R with placebo + Len + R in patients with R/R DLBCL.

View Article and Find Full Text PDF

Diabetes is a growing global health crisis that requires effective therapeutic strategies to optimize treatment outcomes. This study aims to address this challenge by developing and characterizing extended-release polymeric matrix tablets containing metformin hydrochloride (M-HCl), a first-line treatment for type 2 diabetes, and honokiol (HNK), a bioactive compound with potential therapeutic benefits. The objective is to enhance glycemic control and overall therapeutic outcomes through an innovative dual-drug delivery system.

View Article and Find Full Text PDF

Gastrin-releasing peptide receptors (GRPRs) overexpressed in many cancers are known as promising biomarkers to target tumors such as prostate, breast, and lung cancers. As the early diagnosis of the cancers can serve for better treatment of the patients, [In]In-DOTA-Pip-D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2 ([In]In-RM2) was prepared using an in-house developed Sn/In generator. 0.

View Article and Find Full Text PDF

Long-term clinical outcome of a weekly 2-chlorodeoxyadenosine regimen in treatment-naïve patients with hairy cell leukemia.

Ann Hematol

January 2025

Department of Hematology, Seoul St. Mary's Hematology Hospital, College of Medicine, The Catholic University of Korea, Banpo-daero 222, Seocho-Gu, Seoul, South Korea.

Hairy cell leukemia (HCL) has a favorable clinical outcome with appropriate treatment; however, further research is needed on managing patients with relapsed or refractory disease and the risk of infection during prolonged periods. This study examined the long-term effects of 2-chlorodeoxyadenosine (2-CdA), particularly using a weekly infusion protocol, in treatment-naïve patients with HCL. This retrospective study evaluated the long-term follow-up data from 21 South Korean patients diagnosed with HCL.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!